These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mutation of KRAS in colorectal adenocarcinoma in Greenland. Mousavi N; Truelsen SLB; Bernth-Andersen S; Koch A; Heegaard S APMIS; 2022 Aug; 130(8):493-497. PubMed ID: 35655437 [TBL] [Abstract][Full Text] [Related]
6. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Mostert B; Jiang Y; Sieuwerts AM; Wang H; Bolt-de Vries J; Biermann K; Kraan J; Lalmahomed Z; van Galen A; de Weerd V; van der Spoel P; Ramírez-Moreno R; Verhoef C; Ijzermans JN; Wang Y; Gratama JW; Foekens JA; Sleijfer S; Martens JW Int J Cancer; 2013 Jul; 133(1):130-41. PubMed ID: 23233388 [TBL] [Abstract][Full Text] [Related]
7. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients. Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737 [TBL] [Abstract][Full Text] [Related]
8. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. Chen CC; Er TK; Liu YY; Hwang JK; Barrio MJ; Rodrigo M; Garcia-Toro E; Herreros-Villanueva M PLoS One; 2013; 8(2):e55793. PubMed ID: 23437064 [TBL] [Abstract][Full Text] [Related]
9. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887 [TBL] [Abstract][Full Text] [Related]
10. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225 [TBL] [Abstract][Full Text] [Related]
11. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma]. Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307 [TBL] [Abstract][Full Text] [Related]
12. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases]. Gao J; Sun ZW; Li YY; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823 [TBL] [Abstract][Full Text] [Related]
13. IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER. Zanatto RM; Santos G; Oliveira JC; Pracucho EM; Nunes AJF; Lopes-Filho GJ; Saad SS Arq Bras Cir Dig; 2020; 33(3):e1524. PubMed ID: 33331426 [TBL] [Abstract][Full Text] [Related]
14. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer. Ounissi D; Weslati M; Boughriba R; Hazgui M; Bouraoui S Turk J Med Sci; 2021 Feb; 51(1):148-158. PubMed ID: 32892548 [TBL] [Abstract][Full Text] [Related]
16. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer. Kondo Y; Hayashi K; Kawakami K; Miwa Y; Hayashi H; Yamamoto M BMC Cancer; 2017 May; 17(1):311. PubMed ID: 28468669 [TBL] [Abstract][Full Text] [Related]
17. [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]. Gao J; Zhang J; Lu T; Li XY; Jia N; Liang ZY Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):595-8. PubMed ID: 23157826 [TBL] [Abstract][Full Text] [Related]
18. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403 [TBL] [Abstract][Full Text] [Related]
19. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259 [TBL] [Abstract][Full Text] [Related]
20. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. Kalikaki A; Politaki H; Souglakos J; Apostolaki S; Papadimitraki E; Georgoulia N; Tzardi M; Mavroudis D; Georgoulias V; Voutsina A PLoS One; 2014; 9(8):e104902. PubMed ID: 25137394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]